[HTML][HTML] Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron
(B.1.1.529) variant of concern (VOC) has destabilized global efforts to control the impact …
(B.1.1.529) variant of concern (VOC) has destabilized global efforts to control the impact …
[HTML][HTML] Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a …
P Bergman, O Blennow, L Hansson, S Mielke… - …, 2021 - thelancet.com
Background Patients with immunocompromised disorders have mainly been excluded from
clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial …
clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial …
[PDF][PDF] Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination
Many immunocompromised patients mount suboptimal humoral immunity after SARS-CoV-2
mRNA vaccination. Here, we assessed the single-cell profile of SARS-CoV-2-specific T …
mRNA vaccination. Here, we assessed the single-cell profile of SARS-CoV-2-specific T …
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states
Suboptimal immunity to SARS-CoV-2 mRNA vaccination has frequently been observed in
individuals with various immunodeficiencies. Given the increased antibody evasion properties …
individuals with various immunodeficiencies. Given the increased antibody evasion properties …
Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML
…, P Blomberg, BE Wahlin, M Palma, L Hansson… - Clinical Cancer …, 2018 - AACR
Purpose: To evaluate the safety, efficacy, and immunobiological correlates of allogeneic NK-cell–based
therapy in primary chemotherapy-refractory or relapsed high-risk …
therapy in primary chemotherapy-refractory or relapsed high-risk …
SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19
…, S Adamo, O Rivera-Ballesteros, L Hansson… - Science …, 2023 - science.org
T cells are critical for immune protection against severe COVID-19, but it has remained
unclear whether repeated exposure to SARS-CoV-2 antigens delivered in the context of …
unclear whether repeated exposure to SARS-CoV-2 antigens delivered in the context of …
[HTML][HTML] T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
…, E Young, R Rosenquist, L Hansson… - …, 2017 - ncbi.nlm.nih.gov
Chronic lymphocytic leukemia is characterized by impaired immune functions largely due to
profound T-cell defects. T-cell functions also depend on co-signaling receptors, inhibitory or …
profound T-cell defects. T-cell functions also depend on co-signaling receptors, inhibitory or …
[HTML][HTML] Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a …
…, M Mattsson, S Norin, A Sandstedt, L Hansson… - …, 2016 - ncbi.nlm.nih.gov
Ibrutinib, a Bruton’s tyrosine kinase inhibitor is approved for relapsed/refractory and del (17p)/TP53
mutated chronic lymphocytic leukemia. Discrepancies between clinical trials and …
mutated chronic lymphocytic leukemia. Discrepancies between clinical trials and …
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
…, CC Coombs, A Österborg, L Hansson… - Blood, The Journal …, 2021 - ashpublications.org
COI notes: LER has served as a consultant for AbbVie, AstraZeneca, Pharmacyclics, Vaniam
group, and Verastem, holds minority ownership interest in Abbott Laboratories, and has …
group, and Verastem, holds minority ownership interest in Abbott Laboratories, and has …
[HTML][HTML] Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B-and T-cell immunity during 13 months in consecutive patients
…, O Stromberg, M Sällberg Chen, R Zain, L Hansson… - Leukemia, 2022 - nature.com
We studied clinical and immunological outcome of Covid-19 in consecutive CLL patients from
a well-defined area during month 1–13 of the pandemic. Sixty patients (median age 71 y, …
a well-defined area during month 1–13 of the pandemic. Sixty patients (median age 71 y, …
